I 
109TH CONGRESS 
2D SESSION 
H. R. 5940 
To direct the Secretary of Health and Human Services to conduct or support 
a comprehensive study comparing total health outcomes, including risk 
of autism, in vaccinated populations in the United States with such 
outcomes in unvaccinated populations in the United States, and for 
other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 27, 2006 
Mrs. MALONEY (for herself, Mr. OSBORNE, and Mr. HINCHEY) introduced the 
following bill; which was referred to the Committee on Energy and Commerce 
A BILL 
To direct the Secretary of Health and Human Services to 
conduct or support a comprehensive study comparing 
total health outcomes, including risk of autism, in vac-
cinated populations in the United States with such out-
comes in unvaccinated populations in the United States, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Comprehensive Com-
parative Study of Vaccinated and Unvaccinated Popu-
lations Act of 2006’’. 
VerDate Aug 31 2005 
07:11 Jul 29, 2006
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5940.IH
H5940
ycherry on PROD1PC64 with BILLS
SEC. 2. FINDINGS. 
The Congress finds as follows: 
(1) Securing the health of the Nation’s children 
is our most important concern as parents and stew-
ards of the Nation’s future. 
(2) The Nation’s vaccine program has greatly 
reduced human suffering from infectious disease by 
preventing and reducing the outbreak of vaccine-pre-
ventable diseases. 
(3) Total health outcomes are the best measure 
of the success of any public health effort, including 
security from both chronic and infectious disease. 
(4) Childhood immunizations are an important 
tool in the pursuit of childhood health. 
(5) The number of immunizations administered 
to infants, pregnant women, children, teenagers, and 
adults has grown dramatically over recent years. 
(6) The incidence of chronic, unexplained dis-
eases such as autism, learning disabilities, and other 
neurological disorders appears to have increased dra-
matically in recent years. 
(7) Individual vaccines are tested for safety, but 
little safety testing has been conducted for inter-
action effects of multiple vaccines. 
(8) The strategy of aggressive, early childhood 
immunization against a large number of infectious 
VerDate Aug 31 2005 
07:11 Jul 29, 2006
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5940.IH
H5940
ycherry on PROD1PC64 with BILLS
diseases has never been tested in its entirety against 
alternative strategies, either for safety or for total 
health outcomes. 
(9) Childhood immunizations are the only 
health interventions that are required by States of 
all citizens in order to participate in civic society. 
(10) Public confidence in the management of 
public health can only be maintained if these State 
government-mandated, mass vaccination programs— 
(A) are tested rigorously and in their en-
tirety against all reasonable safety concerns; 
and 
(B) are verified in their entirety to produce 
superior health outcomes. 
(11) There are numerous United States popu-
lations in which a practice of no vaccination is fol-
lowed and which therefore provide a natural com-
parison group for comparing total health outcomes. 
(12) No comparative study of such health out-
comes has ever been conducted. 
(13) Given rising concern over the high rates of 
childhood neurodevelopmental disorders such as au-
tism, the need for such studies is becoming urgent. 
VerDate Aug 31 2005 
07:11 Jul 29, 2006
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5940.IH
H5940
ycherry on PROD1PC64 with BILLS
SEC. 3. STUDY ON HEALTH OUTCOMES IN VACCINATED 
AND 
UNVACCINATED 
AMERICAN 
POPU-
LATIONS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services (in this Act referred to as the ‘‘Sec-
retary’’) , acting through the Director of the National In-
stitutes of Health, shall conduct or support a comprehen-
sive study— 
(1) to compare total health outcomes, including 
risk of autism, in vaccinated populations in the 
United States with such outcomes in unvaccinated 
populations in the United States; and 
(2) to determine whether vaccines or vaccine 
components play a role in the development of autism 
spectrum or other neurological conditions. 
(b) QUALIFICATIONS.—With respect to each investi-
gator carrying out the study under this section, the Sec-
retary shall ensure that the investigator— 
(1) is objective; 
(2) is qualified to carry out such study, as evi-
denced by training experiences and demonstrated 
skill; 
(3) is not currently employed by any Federal, 
State, or local public health agency; and 
(4) is not currently a member of a board, com-
mittee, or other entity responsible for formulating 
VerDate Aug 31 2005 
07:11 Jul 29, 2006
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5940.IH
H5940
ycherry on PROD1PC64 with BILLS
immunization policy on behalf of any Federal, State, 
or local public health agency or any component 
thereof; 
(5) has no history of a strong position on the 
thimerosal controversy; and 
(6) is not currently an employee of, or other-
wise directly or indirectly receiving funds from, a 
pharmaceutical company. 
(c) TARGET POPULATIONS.—The Secretary shall 
seek to include in the study under this section populations 
in the United States that have traditionally remained 
unvaccinated for religious or other reasons, such as Old 
Order Amish, members of clinical practices (such as the 
Homefirst practice in Chicago) who choose alternative 
medical practices, and practitioners of anthroposophic life-
styles. 
(d) TIMING.—Not later than 120 days after the date 
of the enactment of this Act, the Secretary shall issue a 
request for proposals to conduct the study required by this 
section. Not later than 120 days after receipt of any such 
proposal, the Secretary shall approve or disapprove the 
proposal. If the Secretary disapproves the proposal, the 
Secretary shall provide the applicant involved with a writ-
ten explanation of the reasons for the disapproval. 
Æ 
VerDate Aug 31 2005 
07:11 Jul 29, 2006
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H5940.IH
H5940
ycherry on PROD1PC64 with BILLS